Literature DB >> 12856715

Phospholipase C-gamma1 in tumor progression.

Alan Wells1, Jennifer Rubin Grandis.   

Abstract

The vast majority of cancer morbidity and mortality arises from tumor progression beyond the primary tumor site. Unfortunately, most therapies are not effective for advanced stage disease with regional extension or distant metastases. Thus, new treatments are needed to target rate limiting steps in tumor progression. The ability of cancers to invade and metastasize requires the acquisition of specific cell behaviors that enable the cell to escape from the localized site, breach the defined boundaries, reach a hospitable ectopic site and grow in this new locale. Recently, dysregulation of cell motility as stimulated by various extracellular factors has gained credence as a rate-limiting alteration in tumor progression in carcinomas and some other solid tumors. This has focused attention on initiators of signaling cascades that regulate tumor migration. In this effort, one molecule, phospholipase C-gamma 1 (PLCgamma), has been shown to function as a key molecular switch.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12856715     DOI: 10.1023/a:1024088922957

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  31 in total

1.  Identification of phospholipase C gamma1 as a protein tyrosine phosphatase mu substrate that regulates cell migration.

Authors:  Polly J Phillips-Mason; Harpreet Kaur; Susan M Burden-Gulley; Sonya E L Craig; Susann M Brady-Kalnay
Journal:  J Cell Biochem       Date:  2011-01       Impact factor: 4.429

2.  Intramolecular regulation of phospholipase C-gamma1 by its C-terminal Src homology 2 domain.

Authors:  Karen DeBell; Laurie Graham; Ilona Reischl; Carmen Serrano; Ezio Bonvini; Barbara Rellahan
Journal:  Mol Cell Biol       Date:  2006-11-20       Impact factor: 4.272

3.  Diverse injurious stimuli reduce protein tyrosine phosphatase-μ expression and enhance epidermal growth factor receptor signaling in human airway epithelia.

Authors:  Sang W Hyun; Ian E Anglin; Anguo Liu; Shiqi Yang; John D Sorkin; Erik Lillehoj; Nicholas K Tonks; Antonino Passaniti; Simeon E Goldblum
Journal:  Exp Lung Res       Date:  2011-06-07       Impact factor: 2.459

Review 4.  Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms.

Authors:  Yuzhe Sun; Edward Davis
Journal:  Nanomaterials (Basel)       Date:  2021-03-16       Impact factor: 5.076

5.  Observations on the effects of Suppressor of Cytokine Signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin Like Growth Factor I (IGF-I).

Authors:  W Sasi; L Ye; W G Jiang; K Mokbel; A Sharma
Journal:  Clin Transl Oncol       Date:  2013-09-18       Impact factor: 3.405

6.  Spatio-temporal modeling of signaling protein recruitment to EGFR.

Authors:  Ming-yu Hsieh; Shujie Yang; Mary Ann Raymond-Stinz; Jeremy S Edwards; Bridget S Wilson
Journal:  BMC Syst Biol       Date:  2010-05-06

Review 7.  Phospholipase signalling networks in cancer.

Authors:  Jong Bae Park; Chang Sup Lee; Jin-Hyeok Jang; Jaewang Ghim; Youn-Jae Kim; Sungyoung You; Daehee Hwang; Pann-Ghill Suh; Sung Ho Ryu
Journal:  Nat Rev Cancer       Date:  2012-10-18       Impact factor: 60.716

Review 8.  Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers.

Authors:  H Wang; L Liang; J-Y Fang; J Xu
Journal:  Oncogene       Date:  2015-08-10       Impact factor: 9.867

9.  Schwann cells induce cancer cell dispersion and invasion.

Authors:  Sylvie Deborde; Tatiana Omelchenko; Anna Lyubchik; Yi Zhou; Shizhi He; William F McNamara; Natalya Chernichenko; Sei-Young Lee; Fernando Barajas; Chun-Hao Chen; Richard L Bakst; Efsevia Vakiani; Shuangba He; Alan Hall; Richard J Wong
Journal:  J Clin Invest       Date:  2016-03-21       Impact factor: 14.808

10.  Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

Authors:  E di Martino; C G L'Hôte; W Kennedy; D C Tomlinson; M A Knowles
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.